The significance of the study:
Given that: (1) 15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD; and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.
Research findings to Therapeutic opportunity:
This study suggests an Oxyntomodulin (OXM)-based therapy for lowering cholesterol and triglyceride levels, and to treat Non-alcoholic fatty liver disease (NAFLD). Oxyntomodulin (OXM), by increasing the expression of its rtrget gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, a pharmaceutical formulations encompassing Oxyntomodulin (OXM) or its activators, either alone or in combination with other drugs, may be used to treat NAFLD (Fig.2).
Figure 1. Mechanistic insights into how Oxyntomodulin (OXM) decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD
Figure 2. Oxyntomodulin (OXM) functions as a cholesterol-lowering agent. Oxyntomodulin (OXM) lowers cholesterol and triglyceride levels and attenuates NAFLD, through down-regulation of HMGCR
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does oxyntomodulin (OXM) decrease the expression of HMGCR and prevent NAFLD?
Amount: $750#
# Research cooperation
For purchase and payment details, you may reach us at info@genomediscovery.org
References:
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Oxyntomodulin-based therapy for lowering cholesterol, and triglycerides levels: Oxyntomodulin (OXM), a 37 amino acid intestinal peptide that inhibits food intake and body weight, decreases the levels of HMGCR, triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 29/April/2019, 2.58 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org